Status:
COMPLETED
Study on Metabolic Parameters of Sertindole in Patients With Schizophrenia
Lead Sponsor:
H. Lundbeck A/S
Conditions:
Schizophrenia
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
The purpose of this exploratory study is to evaluate the effects of sertindole and olanzapine on metabolic parameters and syndrome in patients with schizophrenia.
Detailed Description
The prevalence of metabolic syndrome is estimated to be around 20-25% of the population and is particularly high in patients with schizophrenia. Individuals with metabolic syndrome are twice as likely...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Patients with schizophrenia
- Participation in 11286 study
- Capable of completing all study-related activities for the duration of the study
Exclusion
Key Trial Info
Start Date :
March 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2008
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT00759460
Start Date
March 1 2007
End Date
April 1 2008
Last Update
September 20 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CN002
Beijing, China, 100083